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ABSTRACT
Background: We are developing an immunotherapeutic peptide, Cry-consensus peptide, for Japanese cedar
pollinosis. Cry-consensus peptide is a recombinant polypeptide containing six major human T-cell epitopes de-
rived from both Cry j 1 and Cry j 2, two major allergens of Japanese cedar pollen. We examined the effect of
Cry-consensus peptide on an allergic rhinitis model in B10.S mice, which have one common T-cell epitope in
the Cry-consensus peptide.
Methods: B10.S mice were sensitized with Cry j 1alum, then the Cry-consensus peptide was administered
subcutaneously once a week for 5 weeks from the last sensitization. Histamine was dropped in both nostrils (10
μL per nostril) of each mouse on the day before continuous intranasal instillation of Cry j 1. Soon after the final
challenge with Cry j 1, the mice were observed for 5 minutes for the resulting number of sneezes. In addition,
serum levels of Cry j 1-specific IgE and IgG2a antibody, eosinophil infiltration in nasal tissue, and Cry j 1-
specific cytokine production from splenocytes were evaluated.
Results: Cry-consensus peptide markedly inhibited Cry j 1-induced sneezes, eosinophil infiltration, and
eosinophil peroxidase (EPO) activity in nasal tissue. Cry-consensus peptide inhibited the production of anti-Cry
j 1 IgE (Th2-mediated) and significantly enhanced anti-Cry j 1 IgG2a (Th1-mediated). In cytokine production
from splenocytes, Cry-consensus peptide significantly decreased in IL-4IFN-γ and IL-5IFN-γ ratios.
Conclusions: It was concluded that Cry-consensus peptide effectively controlled allergic responses, which
results from shifting from a Th2-dominated to a Th1-dominated immune response.
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INTRODUCTION
Specific immunotherapy has been widely applied in
the treatment of allergic diseases; it is based on the
administration of increasing doses of disease-eliciting
allergens to induce a state of unresponsiveness to-
ward them.1,2 The results of clinical studies have re-
vealed the availability of specific immunotherapy,3,4
although high doses of allergens caused various side
effects, including anaphylactic reactions.5
Derivatives of several purified and recombinant al-
lergens, including chemically modified allergens6,7
and mutants of wild-type recombinant allergens, have
recently been employed. These derivatives may be
safer as immunotherapeutic agents for treating aller-
gic diseases than the native allergens, since the bind-
ing capacity of the derivatives to allergen-specific IgE
is reduced.
Furthermore, allergen-specific immunotherapy
with synthetic peptides of T-cell epitopes in major al-
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lergens has been reported.8,9 This has involved the
use of short peptides, including T-cell epitopes,
which, by virtue of their size, are incapable of cross-
linking with allergen-specific IgE bound to the sur-
face of mast cells and basophils. Therefore treatment
with T-cell epitope peptides cannot pose the potential
risk of cross-linking with IgE antibodies on mast
cells.
Japanese cedar (Cryptomeria japonica, or Cj) polli-
nosis is one of the most serious type I allergic dis-
eases in Japan. It is prevalent in 10% to 20% of the
Japanese population and poses a significant social
problem.10 Therapies for Cj pollinosis include aller-
gen avoidance, pharmacotherapy using antihista-
mines or corticosteroid nasal spray, and Cj-specific
immunotherapy. Immunotherapy is an effective treat-
ment for patients with allergic rhinitisconjunctivitis,
allergic asthma and allergic reactions from stinging
insects. With this in mind, we produced a curative im-
munotherapeutic drug using Cry-consensus peptide,
the cedar pollen epitope.
For Cry-consensus peptide, we selected multiple T-
cell epitopes from patients with Japanese cedar polli-
nosis. This selection was based on differences among
the types of restriction molecules capable of present-
ing these peptides. Cry-consensus peptide is a recom-
binant polypeptide containing six major T-cell epi-
topes derived from both Cry j 1 and Cry j 2, two major
allergens of Japanese cedar pollen.
In order to investigate new therapeutic approaches,
we established a new experimental model of allergic
rhinitis in B10.S mice where the symptoms are sneez-
ing and eosinophil infiltration into the nasal mucosa,
and induction of antigen specific IgE production after
a continuous intranasal antigen challenge with hista-
mine pretreatment. These symptoms mimic the ma-
jor features of patients with allergic rhinitis.11,12 In
Cry j 1-sensitized B10.S mice, a major T-cell epitope
has been identified,13,14 and the sequence of this epi-
tope coincides with that of the most prevalent epitope
in patients. Cry-consensus peptide has one peptide
that has been described as an important T-cell epi-
tope in B10.S mice immunized with Cry j 1. We pre-
sent direct evidence obtained by in vitro and in vivo
analyses that the on-going allergic immune response
can be modulated by the application of Cry-consensus
peptide in an experimental model of allergic rhinitis.
METHODS
ANIMALS
Female B10.S mice were purchased from Japan SLC
Inc. (Shizuoka, Japan). The animals were housed un-
der controlled conditions of temperature (21 ± 2℃)
and relative humidity (55 ± 15%), fed a standard diet
(CRF-1, Oriental Yeast Co., Ltd., Tokyo, Japan), and
given water ad libitum. All experiments were per-
formed according to the Guiding Principles for the
Care and Use of Laboratory Animals approved by The
Japanese Pharmacological Society.
ANTIGEN
Cry j 1 was purified from Japanese cedar pollen as de-
scribed previously.15 The absence of Cry j 2 in the pu-
rified Cry j 1 preparation was confirmed by Western
blot analysis with two monoclonal antibodies (anti-
Cry j 1 and anti-Cry j 2; Hayashibara Biochemical
Laboratories Inc., Hayashibara Biochemical Laborato-
ries Inc., Okayama, Japan). The purity of Cry j 1 de-
termined by densitometric scanning after sodium do-
decyl sulfate polyacrylamide gel electrophoresis and
Coomassie brilliant blue staining was 88%.
CRY-CONSENSUS PEPTIDE AND DRUG
Cry-consensus peptide (Fig. 1) was expressed in E.
coli and purified in our company.
Histamine dihydrochloride was purchased from
Nacalai Tesque Inc. (Kyoto, Japan).
SENSITIZATION, NASAL ANTIGEN CHALLENGE
AND ADMINISTRATION OF CRY-CONSENSUS
PEPTIDE
Mice were sensitized with 10 μg of Cry j 1 mixed
with 4 mg of aluminum hydroxide gel (Imject Alum,
Pearce, Rockford, IL, USA) by subcutaneous injection
once a week for 3 consecutive weeks. Before continu-
ous intranasal Cry j 1 challenges―5 weeks after the
final sensitization of Cry j 1 and prior to the intranasal
Cry j 1 challenge―1 μgmL of histamine dihydro-
chloride in phosphate buffered saline (PBS) was
dropped into both nostrils (10 μL per nostril) the day
before the first intranasal antigen challenge. On the
day after the histamine pretreatment, 10 μL of Cry j 1
(200 μgmL in PBS) was dropped into each nostril,
using a micropipette, for 5 consecutive days. Soon af-
ter the last intranasal antigen challenge, the number
of sneezes was counted for 5 minutes.
Twenty-four hours after the last intranasal antigen
challenge, the mice were killed and histologically ex-
amined; eosinophil peroxidase (EPO) activity in nasal
tissues was also evaluated, and the serum levels of
Cry j 1-specific IgE, IgG1 and IgG2a were measured.
Cry-consensus peptide was administered subcuta-
neously once a week for 5 consecutive weeks.
HISTOLOGICAL EXAMINATION
For histological examination of the nasal mucosa, the
mouse head was fixed in 10% buffered formalin solu-
tion 24 hours after the last intranasal antigen chal-
lenge. Then the head was severed between the upper
and lower jaws and the facial skin stripped. The tip of
the nose area was decalcified in Plank-Rychlo solu-
tion and embedded in paraffin. Frontal sections of the
nasal tissues were stained with Biebrich scarlet-iron
hematoxylin (Luna stain) to detect infiltrated eosino-
phils.
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Fig. 1 Amino acid sequence of Cry-consensus peptide. The underlines show the 
amino acid sequences of human T cel epitopes; solid underlines; Cry j 1, and dot-
ted underlines; Cry j 2. The #1 peptide (MKVTVAFNQFGPN) is a major T cel epi-
tope in B10.S mice.
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MEASUREMENT OF EOSINOPHIL PEROXIDASE
(EPO) ACTIVITY
Twenty-four hours after the last intranasal antigen
challenge, the tip of the nose area was removed and
homogenized with 5 mL of 0.5% hexadecyltrimethyl-
ammonium bromide (HTAB) in PBS. The homogen-
ate was freeze-thawed three times and the superna-
tant was assayed for EPO after centrifugation. The
supernatant (50 μL ) was mixed with the substrate so-
lution (16 mmolL o-phenylenediamine and 0.01%
H2O2 in 50 mmolL Tris-HCL, pH 8.0) (100 μL) and
the mixture was incubated for 15 minutes at room
temperature. The reaction was stopped by adding 4
molL H2SO4 (50 μL), and the optical density of the
solution was read at 490 nm. Data were expressed in
units of EPO activity, 1 unit being arbitrarily defined
as the activity of 1 × 103 eosinophils isolated from
guinea pigs.
EVALUATION OF SERUM LEVEL OF CRY J 1-
SPECIFIC IgE
On the day following the final intranasal antigen chal-
lenge, mice sera were obtained and the Cry j 1-
specific IgE titer in the serum was evaluated by
enzyme-linked immunosorbent assay (ELISA).
Briefly, 96-well plates (F16 Black Maxisorp, Nalge
Nunc International, Rochester, NY, USA) were
coated with 100 μL of purified rat anti-mouse IgE
monoclonal antibody (50 μgmL, BD Bioscience, San
Jose, CA, USA) in bicarbonate buffer (0.1 molL, pH
8.2) 50 μgmL overnight at 4℃. After removal of the
coating solution, the plates were washed and blocked
with PBS containing 1% bovine serum albumin for 30
minutes at room temperature (RT). After blocking,
the serum samples and standard serum serially di-
luted were added to the plate in duplicate. The stan-
dard serum was obtained by intraperitoneal immuni-
zation of a mouse with Cry j 1 and arbitrary assigned
a value of 10,000 relative units (RU)mL of Cry j 1-
specific IgE. Plates were then washed and incubated
with 100 μL of 12000 diluted Cedar Pollen Allergen
Cry j 1-Biotin (Hayashibara Biochemical Laboratories
Inc.) for 1 hour at RT. The plate was then washed and
subsequently incubated with streptoavidine-β-galacto-
sidase conjugate (Molecular Probes, Eugene, OR,
USA) for 30 minutes at RT. After a final wash, 100 μL
of substrate solution, consisting of Tris-HCl with
0.034 mgmL of 4-methylumberifenyl-β-D-garacto-
pyranocide, was added to the well for 2 hours at 37℃.
The reaction was stopped with 100 μL of glycine-
NaOH, 0.2 molL, pH 10.3, and the fluorescence in-
tensity measured by a microplate fluorescence reader
(Fluoroskan Ascent, Thermo Electron Corp.,
Waltham, MA, USA) at wavelengths of 355 nm (exci-
tation) and 460 nm (emission).
EVALUATION OF SERUM LEVEL OF CRY J 1-
SPECIFIC IgG1 AND IgG2a
Ninety-six-well plates were coated with 50 μL of Cry j
1 (10 μgmL ) overnight at RT, and the plates were
blocked with PBS containing 1% BSA. Then the plates
were washed and incubated with the serum samples
in serial dilution for 2 hours at RT. After the incuba-
tion of the samples, peroxidase-labeled anti-mouse
IgG1 or IgG2a was added to the plate for 1 hour at
RT. Tetramethylbenzidine substrate solution (TMB
Substrate Kit, Pearce, Rockford, IL, USA) was added
to the plate after it had been washed. Finally, 4 molL
of phosphoric acid was added to stop the reaction and
the absorbance at 450 nm was measured with a mi-
croplate reader.
CYTOKINE PRODUCTION INDUCEDWITHCRY J 1
The spleen cells (5 × 105 cellsmL) from control mice
and mice treated with Cry-consensus peptide were
suspended in a 10% FBS in RPMI 1640 culture me-
dium and then cultured in the presence or absence of
Cry j 1 (1 μgmL ) for 48 hours at 37℃ in the 5% CO2
incubator. The levels of IL-4, IL-5 and IFN-γ in the cul-
ture of the supernatant were measured with ELISA
using Opt EIA sets (Pharmingen, San Diego, CA,
USA).
DATA AND STATISTICAL ANALYSIS
The results are presented as means ± SEM For com-
parison among multiple groups, the data were ana-
lyzed for homogeneity of variance using Bartlett’s
test. When the variances were homogeneous, para-
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Fig. 2 Efects of the administration of Cry-consensus peptide on sneezing and EPO activity induced by 
continuous antigen chalenge. A): number of sneezes. B): EPO activities in nasal tissues. Each value rep-
resents the mean ± S.E. of 15 mice. ＊: p＜0.05 (Dunnet’ smultiple comparison test), significant difer-
ence from the control group.
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metric Dunnett’s multiple comparison test was per-
formed. When the variances were not homogeneous
by Bartlett’s test, nonparametric Dunnett’s multiple
comparison test was performed. Student’s t-test or
the Aspin-Welch test was used to evaluate differences
between two groups. A probability value of p < 0.05
was considered to indicate significant differences.
RESULTS
EFFECTS OF CRY-CONSENSUS PEPTIDE ON
CRY J 1-INDUCED SNEEZING AND EPO ACTIV-
ITY
Treatment of the mice with Cry-consensus peptide
suppressed sneezing at doses higher than 0.01 mg
mouse and decreased the number of sneezes to ap-
proximately 50% of that in the control group, although
there were no significant differences between the
control group and Cry-consensus peptide treatment
group (18.5 ± 6.1, Fig. 2A).
To evaluate the number of infiltrating eosinophils,
EPO activity was determined in the tissue homogen-
ate. There was a significant difference between the
control and the treated group―the mean value ±
SEM was 1544 ± 247 in the control group, and 753 ±
86 Ug tissue in the group treated with 1 mg of Cry-
consensus peptide (p < 0.05).
HISTOLOGICAL ANALYSIS OF NASAL TISSUES
A similar inhibiting effect of nasal infiltration of
eosinophil was observed in the histological examina-
tion with Luna staining. On histological examination,
eosinophils were infiltrated into the nasal septum re-
sorptive epithelium, ethmoturbinal concha, back lat-
eral wall and ventral aspect wall, and we classified the
eosinophil infiltration into five degrees (0―4). The
mice unsensitized with Cry j 1 but challenged intrana-
sally with PBS showed no eosinophil infiltration (data
not shown). In the control group, the number of
eosinophils infiltrating into the lamina propria the day
following the last continuous intranasal antigen chal-
lenge was increased (Fig. 3A). The administration of
Cry-consensus peptide reduced eosinophil infiltration
in a dose-dependent manner, especially the mice that
received the dose of 1 mganimal showed very little
eosinophil infiltration (Fig. 3B). However, the num-
ber of mast cells was not affected by the Cry-
consensus peptide treatment (data not shown) . EPO
activity and histological examination in nasal tissue
cannot be evaluated in the same mouse because the
nasal tissue of one mouse has to be used for each ex-
amination. Therefore, we evaluated the EPO activity
and histological examination in half of each group, re-
spectively, and we evaluated the relation between
EPO activity and the findings of histological examina-
tion.
EFFECT OF CRY-CONSENSUS PEPTIDE ON SE-
RUM IMMUNOGLOBULIN LEVEL
There was marked increase in the concentration of
specific IgE antibody in the sera of the control group
(5958 ± 1603 R.U.mL). IgE production in the 1 mg
Cry-consensus peptide-treated mice was inhibited
more than 50% compared with that in the control
group, although there were no significant differences
from the control group (Fig. 4A). Regarding the
antigen-specific IgG1 antibody titer in the sera, there
was no difference between the mice treated with 1
mganimal of Cry consensus peptide, (47.9 ± 10.7
R.U.mL) and the control group (48.8 ± 8.8 R.U.mL)
(Fig. 4B). On the other hand, IgG2a titer (57.0 ± 20.2
R.U.mL ) was higher than that in the control group
(11.0 ± 5.2 R.U.mL ) (Fig. 4C).
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Fig. 3 Histopathological features of Cry j 1-induced alergic rhinitis in B10.S mice at 24 hours after the 
last nasal antigen chalenge. A): Control group, B): Cry-consensus peptide treatment group (1 mg). Eosi-
nophils were stained with Luna and are marked by the arows. Original magnification×200.
Fig. 4 Efects of the administration of Cry-consensus peptide on Cry j 1-specific IgE (A), IgG1 (B) and IgG2a (C) anti-
body levels in mice sera. Each value represents the mean ± S.E. of 15 mice. ＊: p＜0.05 (Dunnet’ smultiple compari-
son test), significant diference from the control group.
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EFFECT OF CRY-CONSENSUS PEPTIDE ON CY-
TOKINE PRODUCTION
Cytokine production from spleen cells after continu-
ous intranasal challenge with Cry j 1 was examined.
Cry j 1-stimulated spleen cells from the control group
produced detectable amounts of IL-4 (34.8 ± 4.0 pg
mL), IL-5 (2662.8 ± 312.1 pgmL) and IFN-γ (1328.1 ±
187.2 pgmL). Application of 1 mg of Cry-consensus
peptide decreased IL-4 (23.9 ± 4.8 pgmL) and IL-5
(1894.1 ± 362.9 pgmL) secretions from spleen cells,
although there were no significant differences from
the control group (Figs. 5A, 5B). On the other hand,
IFN-γ production was slightly increased by the Cry-
consensus peptide treatment (1455.9 ± 262.0 pgmL,
Fig. 5C). The IL-4IFN-γ and IL-5IFN-γ ratios were
significantly lower in the mice treated with 1 mgani-
mal of Cry-consensus peptide than in the control
group (Fig. 6).
DISCUSSION
Immunotherapy using allergen extracts was initially
reported by Noon in 1911.1
It takes several years to acquire tolerance, requires
frequent injections, and immunotherapy has a serious
side effect, namely anaphylaxis.2 Recently, allergen-
specific immunotherapy using short lengths of syn-
thetic peptides has been reported.6,7 The major cat al-
lergen, Fel d 1, the house dust mite allergen, Der p 1
(Dermatophagoides pteronyssinus), and the birch pol-
len allergen, Bet v 1, have been applied in the specific
immunotherapy of these allergies.8,9,16 Peptide immu-
notherapy is safe and clinically effective, and several
clinical and experimental studies have been reported
on the use of T-cell peptides in immunotherapy.17
In Japan, the number of patients presenting with
pollinosis has continued to increase from the 1970s,
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Fig. 5 Efects of the administration of Cry-consensus peptide on Cry j 1-induced IL-4 (A), IL-5 (B) and 
IFN-γ (C) production. Each value represents the mean ± S.E. of 15 mice.
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and 35% of Japanese people are estimated to have an-
tibodies to cedar pollen, and about 20% suffer from
pollinosis. We have developed Cry-consensus peptide
for the treatment of Cj pollinosis. Cry-consensus pep-
tide is a recombinant polypeptide containing six types
of T-cell epitope with an arginine dimer. In our pre-
liminary study, no binding of IgE in sera from the al-
lergic patients to Cry-consensus peptide was ob-
served. So Cry-consensus peptide did not function as
an allergen to induce allergic reactivity. In a previous
study, we established an allergic rhinitis model in
B10.S mice.18 In this model, Cry j 1, one of two major
allergens in Japanese cedar pollen, induced sneezing,
nasal eosinophil infiltration, and increased serum lev-
els of Cry j 1-specific IgE as a result of repeated Cry j
1 challenges, administered intranasally. In our rhini-
tis model, histamine pretreatment enhances the local
sensitivity to allergen at the nasal mucosa and also
the systemic reactions to allergen, such as allergen-
specific IgE production. Pretreatment with histamine
may cause the opening of the intraepithelial tight
junctions, allowing the penetration of allergen into
the epithelium and lamina propria, where allergen
further interacts with sensitized mast cells.19 In this
study, we have demonstrated the efficacy of Cry-
consensus peptide in the allergic rhinitis model in
B10.S mice. Administration of Cry-consensus peptide
at a dose that was higher than 0.01 mgmouse sup-
pressed sneezing, and reduced its frequency by ap-
proximately 50%, when compared with the control
group.
Eosinophils release proinflammatory mediators
successively, including cysteinyl leukotrienes, cat-
ionic proteins, and eosinophil peroxidase.20 Eosino-
phils play an important role in nasal hypersensitivity
in allergic rhinitis,21 and they are the predominant
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cells in the chronic inflammatory process that is char-
acteristic of the late-phase allergic response. Continu-
ous intranasal antigen challenges led to infiltration by
eosinophils into the nasal tissue. EPO was used as a
marker enzyme to measure tissue eosinophil con-
tent.22 The results of the histopathological examina-
tion and EPO activity in this allergic rhinitis model
showed that Cry-consensus peptide suppressed
eosinophilic infiltration into sites of allergic inflamma-
tion in a dose-dependent manner. Another rhinitis
model that is being established in Cry j 2-sensitized
BALBc mice has been reported which enables the
evaluation of symptoms and reactions associated with
allergic rhinitis.23,24 In this model, increases in sneez-
ing frequency, the vascular permeability of the nasal
mucosa, and hyperreactivity to histamine occurred by
challenging the mice with a Cry j 2 solution, intrana-
sally. In our model, eosinophilic infiltration can be
evaluated by measuring the level of EPO activity in
the nasal tissue. These results suggest that treatment
with Cry-consensus peptide may inhibit the develop-
ment of rhinitis.
In our rhinitis model, repeated and continuous in-
tranasal antigen challenge significantly increased
anti-Cry j 1 IgE levels when compared with those lev-
els measured before the intranasal antigen challenge.
Treatment with Cry-consensus peptide reduced lev-
els of anti-Cry j 1 IgE in a dose-dependent manner.
This reduction in anti-Cry j 1 IgE levels may relate to
the decrease in the frequency of sneezing. On the
other hand, Cry-consensus peptide significantly
raised the production of IgG2a. IgE is positively regu-
lated by IL-4, which is secreted by Th2 cells.25 Th1
cells promote immunoglobulin class switching to
IgG2a due to the production of IFN-γ.26 These results
suggest that Cry-consensus peptide induces a qualita-
tive alteration from Th2 to Th1.
To clarify the mechanisms involved in the inhibi-
tion of allergic rhinitis, we examined cytokine produc-
tion from spleen cells that had been taken from mice
with rhinitis and stimulated with Cry j 1 in vitro.
When animals had been administered Cry-consensus
peptide at a dose of 1 mganimal, the production of
Th2 cytokines, such as IL-4 and IL-5, was lower than
that in the control group. In contrast, the production
of the Th1 cytokine, IFN-γ, was a little higher in the
group of animals administered Cry-consensus peptide
at a dose of 1 mganimal than in the control group.
The immunopathological features of allergic rhini-
tis are associated with the effects of Th2-derived cy-
tokines.27,28 Higher levels of Th2-derived cytokines,
including IL-3, -4, -5, -13, and GM-CSF, have been de-
scribed in allergic rhinitis. The Th2-type cytokines,
IL-4 and IL-5, thought to play a crucial role in type I
allergy, were down-regulated, while the Th1 cytokine,
IFN-γ, was higher or unchanged after successful im-
munotherapy.29,30 In this study we also observed the
down-regulation of IL-4 and IL-5 production in spleno-
cytes. The cytokine ratios IL-4IFN-γ and IL-5IFN-γ,
produced from the splenocytes, were lower in the
mice treated with Cry-consensus peptide at a dose of
1 mganimal than in the animals in the control
group. Determination of the IL-4IFN-γ and IL-5IFN-
γ ratio could be a sensitive approach towards evaluat-
ing the Th1Th2 balance. The immune responses of
the mice could be altered qualitatively based on their
cytokine secretion patterns from Th2 to Th1 through
treatment with Cry-consensus peptide. It was clear
that the ratio of Cry j 1-specific IgEIgG2a directly
correlated with the ratio of IL-4IFN-γ and IL-5IFN-γ
in vitro. The mechanism of action of Cry-consensus
peptide may involve switching from a Th2 to a Th1
cytokine profile.
In conclusion, our results demonstrate that treat-
ment with Cry-consensus peptide can inhibit nasal tis-
sue eosinophilia, antigen-specific IgE production, and
the production of Th2 cytokines from splenocytes in
an allergic rhinitis mice model. These results suggest
that Cry-consensus peptide could be a new immuno-
therapeutic agent effective against Cj pollinosis by
shifting from a Th2-dominated to a Th1-dominated
immune response.
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